TenQ

The Cigna story

Cigna combines health insurance with Evernorth's pharmacy services, with the central question whether specialty drug growth can offset weaker pharmacy benefit earnings as it changes how customers receive drug discounts.

Written from Cigna's own filings with the SEC, and rewritten when it publishes a new earnings release. Updated 2026-09-30.

  • $271.83share price, last close
  • $71.8Bmarket value
  • 15/36TenQ Score checks passed

The story in brief

  • Specialty offsets pressure. In the quarter to June 2026, Specialty and Care Services increased adjusted pretax operating income 22%, but Evernorth's total fell 2% as Pharmacy Benefit Services earnings declined.
  • Employer plans strengthen. Cigna Healthcare increased adjusted pretax operating income 17% in the quarter to June 2026, primarily through an improved margin in its U.S. Employer business.
  • Debt limits flexibility. Cigna has $31.9 billion in total debt against $7.3 billion in cash and short-term investments, and passes 1 of 6 TenQ financial health checks.

What drives the business

  • Evernorth serves large pharmacy clients through Express Scripts, including a multiyear Centene agreement that began January 1, 2024, agreements with Prime Therapeutics, and the military health program TRICARE.
  • Its pharmacy network, home delivery operations and Accredo specialty pharmacy connect drug purchasing and patient care, with Evernorth generating $61,468 million in adjusted revenue in the quarter to June 2026.
  • Cigna plans to introduce its pharmacy benefits model without rebates for fully insured Cigna Healthcare customers beginning in 2027 and make it the standard model available to Evernorth pharmacy benefit clients beginning in 2028, moving negotiated drug discounts to the pharmacy counter.
  • Cigna Healthcare combines insurance with administration of employer-funded plans, with administrative services arrangements accounting for approximately 32% of segment revenue in 2025 and 79% of medical customers as of December 31, 2025.
  • Specialty and Care Services earnings growth in the quarter to June 2026 reflected organic growth, greater generic and biosimilar adoption, and operating efficiencies, while Pharmacy Benefit Services earnings fell 27%, primarily reflecting client and customer initiatives, including large contract renewals.

What the price assumes

TenQ does not measure a growth assumption through a reverse DCF for Cigna because an insurer's free cash flow does not measure what it earns.

At $271.83, Cigna's price to earnings ratio is 11.4x, and its earnings yield of 8.8% clears TenQ's 5.2% Treasury comparison.

Revenue grew 7.8% over the last twelve months against a 15.0% annual pace over the last three years, failing TenQ's check for accelerating growth despite profits growing 27.9% over the last twelve months.

What could change the story

  • Pharmacy customers fell 4% from December 31, 2025 to 118.2 million at June 30, 2026, reflecting expected client transitions and lower membership among health plan clients.
  • Cigna Healthcare's medical care ratio reached 84.5% in the quarter to June 2026 versus 83.2% a year earlier, primarily reflecting higher prior year risk adjustment benefits recognized in the earlier period, while claims exceeding estimates remain a risk to margins.
  • Express Scripts assumes the risk of securing sufficient rebates under some client guarantees, making manufacturer negotiations and changes in drug pricing important to contract profitability.
  • TenQ's investment income coverage check is 0.74 against a 5.00 benchmark, and its debt trend check fails, highlighting financing constraints alongside the planned pharmacy model transition.
  • Cigna's planned exit from the Individual and Family Plans medical business as of January 1, 2027 adds another operating change alongside the pharmacy transition.

What to watch next

  • The next releases will test Cigna's raised full year 2026 adjusted income from operations outlook of at least $30.45 per share, which includes expected future share repurchases.
  • Evernorth's full year 2026 adjusted pretax operating income outlook is at least $6,900 million, making the balance between specialty growth, pharmacy contract economics and customer retention central to progress.
  • Cigna Healthcare's full year 2026 outlook calls for at least $4,550 million in adjusted pretax operating income and a medical care ratio between 83.7% and 84.7%.
  • Further details on client adoption and economics of the pharmacy benefits model without rebates will help show how the planned transition affects Evernorth.

Sources

Back to the CI report